Lumoxiti (moxetumomab pasudotox)

News alerts, weekly reports and conference planners

Company:

AstraZeneca

Drug class:

Protein synthesis inhibitor, CD22-targeted cytotoxin

Related drugs:

No biomarker	Hairy Cell Leukemia	No biomarker	Hairy Cell Leukemia	moxetumomab pasudotox Sensitive: A1 - Approval moxetumomab pasudotox Sensitive : A1	moxetumomab pasudotox Sensitive: A1 - Approval moxetumomab pasudotox Sensitive : A1
CD22 positive	Lymphoma	CD22 positive	Lymphoma	moxetumomab pasudotox Sensitive: C2 – Inclusion Criteria moxetumomab pasudotox Sensitive : C2	moxetumomab pasudotox Sensitive: C2 – Inclusion Criteria moxetumomab pasudotox Sensitive : C2

Associations
(2)